Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMS) is an American biopharmaceutical company that discovers, develops, licenses, manufactures, and markets a wide range of biopharmaceutical products worldwide. BMS is headquartered in New York and has a robust global presence with manufacturing, research and development sites in several countries around the world.

Founded in 1887 when two men, William McLaren Bristol and John Ripley Myers, formed a partnership to market medicines, BMS was originally called Bristol-Myers Company. Over the years, it has evolved as a major player in the biopharmaceutical industry and has made significant contributions to the world of healthcare.

BMS offers a portfolio of medicines for a wide range of serious illnesses, including hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. Some of BMS’s most notable products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. These drugs are sold through major pharmaceutical wholesalers, distributors, hospitals, clinics, and government agencies.

In addition to its development of medicines, BMS is also an active participant in innovative research and development initiatives and has partnered with leading institutions to support its groundbreaking work. The company has made significant investments in the development of new technologies, such as genomic sequencing, computer modeling, and data analysis, to improve its medicines and provide better solutions to its customers. It is also heavily involved in clinical research and has several ongoing clinical trials in different countries.

BMS is committed to improving patient outcomes and advancing global health and has made significant contributions in the fight against serious illnesses. The company continues to develop new treatments and technologies to address the world’s toughest health challenges and ensure the best care for its customers.